Introduction
In 2008 more than 16 000 patients receiving high-dose therapy (HDT) supported by auto-SCT were reported to the European Blood and Marrow Transplantation registry.
The most common indications included plasma cell disorders mostly multiple myeloma (MM) (n ¼ 6694), non-Hodgkin lymphoma (NHL, n ¼ 4815) and Hodgkin lymphoma (n ¼ 1919).
1 More than 98% of the transplants in adults were performed using blood stem-cell grafts. The obvious advantages of blood stem-cell grafts over BM grafts include easy collection in the majority of patients and more rapid neutrophil and platelet engraftment and hence less need for supportive care after HDT. With regard to engraftment, dose of blood CD34 þ cells given to the patient is important. In addition to CD34 þ content, other graft characteristics (Table 1 ) may also be important including various lymphocyte subsets, natural killer (NK) cells and DCs. These characteristics may have important clinical consequences for patient outcome after stem-cell infusion following HDT and will be the focus of this review. We will also discuss the relation between mobilization regimen used and graft content with special reference to the recently approved use of plerixafor for stem-cell mobilization.
CD34
þ cell dose and engraftment
The number of CD34 þ cells has been considered the most important graft parameter for almost two decades. Several studies have confirmed the relation between CD34 þ cell dose and engraftment, especially platelet engraftment. [2] [3] [4] [5] [6] [7] [8] Higher CD34
þ doses are associated with shorter febrile periods, as well as less needed for supportive care and reduced costs associated with auto-SCT. 4 There are some studies showing that the optimal CD34 þ cell dose should be at least 5 Â 10 6 /kg. 5 In many transplant centres the minimum blood graft is at least 2 Â 10 6 /kg CD34 þ cells for a single transplant. The International Myeloma Working Group suggested collection of at least 4 Â 10 6 /kg CD34 þ cells for a single autotransplant and 8-10 Â 10 6 /kg to allow two transplants when feasible. 9 The optimum dose has not been properly evaluated taking into consideration the requirement for durable engraftment, costs of supportive care as well as costs of mobilization, collection and logistics in the stem cell laboratory.
The number of CD34 þ CD38 À cells may be important for early engraftment after HDT, 10-12 whereas long-term engraftment seems to be dependent merely on the dose of CD34 þ cells infused. 12 Numbers of CD34 þ CD110 þ cells seem to be also of importance for long-term platelet engraftment. 13 Henon et al. 10 showed that CD34 þ CD38 À doses as low as 5 Â 10 4 /kg resulted in rapid and sustained engraftment after HDT. A combination with G-CSF plus plerixafor mobilized eightfold more CD34 þ CD38 À cells when compared with mobilization with G-CSF alone. 14 This indicates that in patients who mobilize poorly, fewer CD34 þ cells may be needed for durable haematopoietic engraftment if they have received plerixafor before collection of blood stem cells. Similarly, the number of long-term culture initiating cells was significantly higher in patients mobilized with G-CSF plus plerixafor when compared with mobilization with G-CSF alone.
14 These may be the reasons for more frequent full platelet engraftment (platelet counts 4150 Â 10 9 /L) at 6 months from auto-SCT in myeloma patients receiving G-CSF plus plerixafor-mobilized stem cells (91%) 15 when compared with patients mobilized with chemotherapy (CT) þ G-CSF (65%).
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CD34
þ cell dose and outcome
Several studies have evaluated the relation of CD34 þ cell dose and to patient outcome after auto-SCT. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] These studies are summarised in Table 2 . The general impression is that better blood stem-cell mobilization or a higher CD34 þ cell dose is associated with superior-outcome post transplant. In fact, only one study in lymphoma patients, 16 one study in MM patients 18 and a study including 358 patients with several diseases 26 have not reported this association. The background for this observation is unclear. Higher amounts of CD34 þ cells infused may improve outcome by allowing more rapid haematopoietic reconstitution but as early non-relapse mortality is in general very low (in the order of 1-2% in myeloma patients and 2-4% in lymphoma patients), this is not likely to be the main explanation. Other possible contributors include patient and disease-related characteristics, as well as the effect of previous CT, all potentially influencing mobilization capacity. It is possible that patients who mobilize less well have other poor risk features (higher age, more advanced disease, more resistant disease or have received more CT courses), but as the CD34 þ cell dose given to support HDT has also seemed to be of prognostic significance in multivariate analysis, this issue is intriguing. Further, it is not known whether better outcome in superior mobilizers is due to the higher number of CD34 þ cells infused or due to other characteristics of the graft such as lymphocyte subsets, NK cells or DCs. If higher CD34 þ cell counts really matter, more efforts to increase stem-cell mobilization such as adding plerixafor to the mobilization regimen, should be considered.
Immunological recovery post transplant
In addition to haematopoietic reconstitution, graft characteristics apparently have an important role in terms of immunological recovery following HDT. There are several reports suggesting lower risk of relapse and thus better PFS in patients with rapid lymphocyte recovery defined as the Optimizing blood graft content in auto-SCT E Jantunen and S Fruehauf absolute lymphocyte count on day þ 15 after stem-cell infusion. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] These studies are summarized in Table 3 . The number of lymphocytes within the graft infused seems to have prognostic significance potentially by affecting early lymphocyte recovery. 38, 40, 41 Numbers of NK cells in the graft may be important to ensure rapid immune reconstitution. 42 Further, the number of CD8 þ cells in the graft seems to be important for early lymphocyte recovery. 43 There are currently insufficient data regarding the relation of graft CD34 þ cell content per se and immune recovery. It is possible that grafts containing higher numbers of CD34 þ cells might also contain more T cells, NK cells and DCs, but this issue clearly deserves further study. Previous CT may not only affect the mobilization capacity of CD34 þ cells, but also that of other subtypes needed for rapid immune reconstitution.
Immune reconstitution is important not only to prevent infections post transplant, but also to lay the ground for post-transplant manipulation of the immune system for example by lenalidomide maintenance therapy post auto-SCT in myeloma patients 44, 45 or vaccination strategies currently under clinical evaluation. 46 
Lymphocyte content of the graft
Two studies have reported an association between the number of lymphocytes infused and outcome in myeloma patients 38, 41 and one study in NHL patients. Further, the study of Holtan et al. 47 suggested that mobilization with G-CSF plus plerixafor was associated with more effective mobilisation of lymphocytes. They showed better PFS in a small number of NHL patients mobilized with G-CSF plus plerixafor when compared with patients mobilized with G-CSF alone (relapses in 0/7 versus 15/29 patients).
DCs may also be important graft components. Dean et al. 48 evaluated the number of DCs, as well as DC subsets 1 and 2 in the graft and in blood samples after 6 weeks from stem-cell infusion in patients with diffuse large B-cell lymphoma. Higher pre-transplant DC counts and higher numbers of DC1 cells were associated with improved survival. Moreover, DC levels at 6-weeks post transplant were associated with survival. In the study reported by Rettig et al., 49 plerixafor mobilized more CD34 þ CD45RA þ cells which were shown to be DC2 precursors when compared with mobilization with G-CSF.
Tumour cell contamination of the graft
There have been some reports suggesting that tumour contamination of the graft may influence post-transplant outcome in myeloma patients, 50, 51 although the opposite results have also been presented. 52 CD34 þ cell selection of the graft became quite popular more than a decade ago. However, two randomized studies evaluating the importance of CD34 þ cell selection in myeloma patients showed that the outcome was not affected by graft selection despite a 2-3 log decrease in the amount of tumour cells 53,54 and currently CD34 þ cell selection is rarely performed in the autologous setting, with the possible exclusion of some clinical study protocols for treatment of severe autoimmune diseases.
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þ cell selection of the graft affects not only the potential tumour cell contamination, but also importantly the amount of accessory and immune cells given to the patient to support HDT. Optimizing blood graft content in auto-SCT E Jantunen and S Fruehauf
It is possible that the potential benefits of CD34 þ cell selection in regard to decreased tumour-cell contamination in the graft are offset by the negative effects of giving fewer CD34 þ cells (due to cell loss during processing), but perhaps more importantly due to slower immunological reconstitution after HDT caused by lower amounts of various lymphocyte subsets in the graft.
Apheresis products collected after either mobilization with CT plus G-CSF or those mobilized with G-CSF alone have been shown to be contaminated with tumour cells. 69, 70 In clinical studies, mobilization with G-CSF plus plerixafor has not caused excessive tumour cell mobilization when compared with mobilization with G-CSF alone [71] [72] [73] There are no published data on tumour cell mobilization after CT plus G-CSF mobilization followed by plerixafor.
Effect of mobilization regimen on graft characteristics
Mobilization regimens that are used may have an important impact on graft characteristics (Table 4) , which may have important long-term consequences for the patient.
At present the number of CD34 þ cells collected remains the most important parameter for efficient blood stem-cell mobilization and collection in clinical practice. In general CT plus G-CSF mobilizes 2-3 times more CD34
þ cells than G-CSF alone, 74 although there may be no major differences between these approaches in the subgroup of patients who are hard-to-mobilize. 75 On the basis of two phase III studies, 15,76 a combination of plerixafor and G-CSF is more efficient than G-CSF alone for mobilization of stem cells in MM and NHL patients. There are no prospective comparisons between CT plus G-CSF vs G-CSF plus plerixafor mobilization. However, successful collection with G-CSF þ plerixafor in a high percentage of patients who have failed CT þ G-CSF mobilization 77 suggests that G-CSF þ plerixafor may be more effective at least in poor mobilizers.
As the combination of CT þ G-CSF mobilizes more CD34 þ cells than G-CSF alone, 78 a triple combination (CT þ G-G-CSF þ plerixafor) is obviously the most effective mobilizing regimen currently in use. In the largest feasibility study published, addition of plerixafor to CT þ G-CSF mobilisation resulted in a mean two-fold increase in myeloma patients and 2.15-fold increase in NHL patients in the number of CD34 þ cells collected when compared with the collection on the day of plerixafor administration. 79 In a small group of patients who mobilized poorly with chemomobilization, a several fold increase in blood CD34 þ counts after plerixafor has been reported, 80, 81 further evidence supporting the superior potential for this combination. The triple combination is the obvious choice whether very high CD34 þ collection yields are needed. Rescue use of plerixafor is very efficient 80, 81 in patients who mobilize poorly and is likely to be the most cost-effective way of increasing collection yields and decreasing the number of aphaeresis sessions in poor mobilizers.
If high CD34 þ cell doses in the autologous setting really have an impact on patient outcomes in addition to timely haematopoietic recovery, then the most efficient mobilization method is preferable taking into account also costs and convenience. In good mobilizers, CT may not be needed at all and plerixafor can be added to G-CSF mobilization. In patients with active lymphoma, CT is often needed to control the disease and plerixafor might be added, if blood CD34 þ cell counts remain low at the time of haematopoietic recovery or if the first collection yields are poor. In poor mobilizers, evaluation of minimal CD34 þ CD38
À cell doses for successful engraftment might be important as patients mobilizing fewer than 2 Â 10 6 /kg CD34 þ cells or even fewer than 1 Â 10 6 /kg will be identified. It is known that a combination of G-CSF and plerixafor mobilizes more CD34
þ CD38 À cells than does G-CSF alone.
14 Therefore it is possible that lower CD34 þ cell doses are needed for adequate engraftment if the patient has been mobilized with plerixafor but this issue needs further study.
Limited data are available on the effect of mobilization regimen used and the various lymphocyte subsets in the graft. In healthy donors, a combination of G-CSF and plerixafor mobilized 2-3 times more B lymphocytes (CD19 þ ) and T lymphocytes (CD2
þ ) than G-CSF alone. 82 In myeloma patients G-CSF mobilized more lymphocytes than a combination of cyclophosphamide and G-CSF. 83 G-CSF plus plerixafor mobilized more lymphocytes 47 and DCs 84 in NHL patients than did G-CSF alone. GM-CSF may mobilize more DCs than G-CSF in NHL. 85 Etoposide plus G-CSF Optimizing blood graft content in auto-SCT E Jantunen and S Fruehauf mobilization resulted in lower numbers of DCs type 2 when compared with mobilization with G-CSF alone. 86 Mobilization with G-CSF induces a Th2 phenotype in lymphocytes. Plerixafor does not induce a significant shift in Th1 and Th2 cell subsets at least in allogeneic donors. 87 One might therefore argue that for infection control after autologous transplantation, plerixafor-mobilized grafts might be superior to G-CSF-mobilized grafts. However, this issue need to be confirmed in the autologous setting.
Gene expression profiling studies have indicated that the mobilization regimen used may affect not only the number of various cell types, but also gene expression of the CD34 þ cells collected. In the study by Fruehauf et al., 88 expression of genes for chemokine receptor 4 (CXCR4), anti-apoptosis, cell cycle promotion, cell adhesion and cell motility were higher in collections after G-CSF plus plerixafor mobilization when compared with the collections after G-CSF mobilization alone. No data are available on gene expression of CD34 þ cells in patients mobilized with CT þ G-CSF þ plerixafor.
Areas for further studies
Taking into account that blood stem-cell mobilization and collection to support HDT for various malignancies has been used widely for about two decades, relatively little is known about the importance of graft characteristics other than those associated with durable haematopoietic engraftment. As relapse is clearly the major reason for treatment failure in patients with haematological malignancies after auto-SCT, further studies in this field are clearly warranted. Limited improvements in terms of long-term survival are likely to result from improving current supportive care, as early mortality in the autologous setting is already low. Furthermore, several clinical trials aiming at increasing anti-tumour efficacy of high-dose regimens over two decades or so have generally resulted in increased regimen-related toxicity without improvement in PFS or OS.
Studies evaluating graft composition in relation to patient outcome have been mostly retrospective. Findings presented and discussed in this review, although intriguing, need to be confirmed in prospective studies as there are likely to be several potential confounding factors. Further, the optimal CD34 þ cell dose has to be defined in prospective studies. Long-term follow-up of phase III studies using G-CSF plus plerixafor mobilized stem cells compared with G-CSF mobilized stem cells in MM patients 15 or NHL patients 76 will give some hints as to whether giving higher numbers of CD34 þ cells or other constituents of the graft will result in improved patient outcome. Further, more detailed evaluation of graft characteristics in these studies may help to identify which graft components are more important for patient outcome. If the use of plerixaformobilized stem cells results in superior outcome in terms of relapse risk and survival, then its use should become routine.
It is also important to conduct prospective studies evaluating the effects of high CD34 þ cell dose (for example, 5-10 Â 10 6 /kg) compared with standard dose (for example, 3-5 Â 10 6 /kg) in terms of immune reconstitution (lymphocyte subsets, NK cells and DCs). These high doses can now be easily collected in the majority of MM patients using a combination of G-CSF and plerixafor, 15 but remain harder to reach in a significant percentage in patients with NHL. 76 To increase the number of NHL patients with high collection yields, a combination of CT with G-CSF followed by plerixafor should also be evaluated. There are practically no data on composition of grafts collected after this mobilization strategy in terms of numbers of NK cells, DCs, other lymphocyte subsets and gene expression profile of CD34 þ cells. A randomized comparison of G-CSF þ plerixafor compared with CT þ G-CSF þ plerixafor would also be interesting in lymphoma patients. In addition to the number of CD34 þ cells collected and number of apheresis needed, an evaluation of other graft components and gene expression profiling of CD34 þ cells should be included, combined with data on haematological and immunological reconstitution and outcome.
At present, pre-freeze CD34 þ content of the graft remains the most decisive marker of CD34 þ dose given to support HDT and the most widely used marker of graft content. However, considering recent advances in this field, the number of CD34 þ CD38 À cells may also be important, as well as possibly number of CD34 þ CXCR4 þ cells. Post-thaw viability of plerixafor-mobilized CD34 þ cells may be lower that that of G-CSF-mobilized CD34 þ cells due to the higher proportion of CD34lowCD45RA þ DCs precursors, which have more granules. Some of these cells may not survive the freeze-thaw process, although primitive CD34 þ CD38 À cells will survive. Use of plerixafor alone before blood stem-cell collection is under clinical evaluation. 89 At present a single dose of plerixafor followed by collection seems to be the simplest way to obtain stem cells but further studies in relation to efficacy, graft content and long-term effects are needed.
Current indications for use of plerixafor in the EU include patients with lymphoma or MM who mobilize poorly. Other potential indications being studied include poor mobilizers with testicular cancer and those with paediatric solid tumours. 90 There are emerging data that the mobilization regimen used has an effect on gene expression of cells collected. 91 These may include genes involving apoptosis, cell adhesion and cell cycle. Clinical consequences of these genetic changes induced by mobilization therapy should also be evaluated as a part of prospective clinical studies.
Conclusions
Graft characteristics are important in auto-SCT recipients not only to ensure adequate haematopoietic engraftment after HDT, but also to allow appropriate immune reconstitution. Several retrospective studies have suggested that graft characteristics may be important predictors for PFS and OS in patients receiving auto-SCT. Various mobilization strategies result in potentially important differences in graft characteristics and content. Addition of plerixafor for patients who mobilize poorly together with individually tailored sizing of apheresis enables harvesting of minimal and optimal CD34 þ cell doses for
Optimizing blood graft content in auto-SCT E Jantunen and S Fruehauf transplantation within a minimum number of aphereses. Clearly, further studies are needed to ascertain the optimal composition of the blood stem-cell graft in relation to short and long-term outcomes. These may include issues related to various lymphocyte subsets, which are already known to be important in allogeneic transplantation 90 in addition to higher CD34 þ cell dose but prospective data in the autologous setting are scarce. All of these issues may have major implications in the near future in relation to the so-called optimal stem-cell mobilization regimen in the autologous setting.
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